The contract research organization (CRO) PPD and NeoGenomics, which specializes in cancer genetics testing and information services, have opened the doors at a new oncology-focused clinical trials testing lab.
The expansion stems from a strategic alliance established in 2018 and, in the same building as the PPD Laboratories central lab, will help advance the companies’ initiative to provide a global solution for drug development programs in the region. It also boosts PPD’s specialized oncology and pathology biomarker testing offerings, according to the CRO.
“As today’s global clinical trials become more complex and there is an increased demand for pathology services in the Asia‐Pacific region, PPD Laboratories’ central lab has been building its pathology and molecular service offerings to support our clients’ clinical trials with an integrated solution,” said Christopher Fikry, MD, executive vice president, PPD Laboratories.
As part of the alliance, NeoGenomics has been providing a range of lab testing services to support PPD Laboratories’ oncology clinical trial activities in North America, Europe, and Asia-Pacific
“NeoGenomics’ extensive experience with oncology trials and cancer-focused genetic testing supplements PPD's internal anatomic pathology capabilities and strengthens its offering for clinical trials, particularly oncology trials,” Fikry told us.